ShanghaiJune 15, 2026 /PRNewswire/ — In the height of summer, Suzhou was filled with distinguished guests. From June 11 to 14, 2026, the 20th Asia-Pacific Congress of Cardiovascular and Interventional Radiology (APSCVIR 2026) was grandly held at the Suzhou International Expo Center. The congress was chaired by Academician Teng Gaojun of the Chinese Academy of Sciences, bringing together over a thousand elite scholars in the field of interventional medicine from around the world. Meijie Medical showcased its new “i” series multimodal tumor treatment technology, becoming the focal point of the congress with its cutting-edge innovative concepts, breakthrough clinical data, and intelligent upgrade solutions, garnering significant attention and widespread recognition from global experts.
Clinical Evidence Breakthrough: Multimodal Technology Turns “Cold Tumors” into “Hot Tumors”
Meijie Medical’s globally pioneering, self-developed multimodal tumor treatment technology is genuinely reshaping the treatment landscape for solid tumors such as liver cancer and pancreatic cancer. By utilizing rapid shear of ultra-low temperature freezing and radiofrequency heating, along with precise thermal dose control, this technology not only achieves efficient in-situ inactivation of tumor cells but also fragments tumor cells and efficiently releases tumor antigens, transforming traditionally immunologically “cold” tumors into “hot” tumors sensitive to immunotherapy. This technology has been approved for market release through the innovative medical device special review process, and its groundbreaking clinical value has been highly recognized by the international academic community:
- Authoritative Validation: Related mechanistic studies and clinical results have been featured on the cover of Theranostics. Research shows that multimodal tumor treatment can significantly prolong progression-free survival in patients with advanced liver cancer. For the first time, it was discovered that CX3CR1⁺GPR56⁺ tumor-reactive CD8⁺ T cells are a key functional subset mediating long-lasting anti-tumor immunity. This subset significantly enriches in the periphery after treatment, and its expansion ratio is significantly positively correlated with patient progression-free survival.
- Major Release: At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Meijie Medical released the latest data in the field of pancreatic cancer treatment. Multimodal therapy transforms pancreatic tumors from “cold” to “hot,” and when combined with immunotherapy, extends patient overall survival by 8 months compared to traditional chemotherapy regimens, bringing new hope for the treatment of the “king of cancers.”
- Widespread Application: This technology has received support from the 2025 National High-End Medical Equipment Promotion and Application Project by the Ministry of Industry and Information Technology and the National Health Commission. It has achieved comprehensive cross-department clinical application in interventional radiology, hepatobiliary surgery, thoracic surgery, and oncology departments at over ten leading hospitals in China.
Intelligent Upgrade: “i“Series Debuts, Digital Twin Empowers Precision Treatment
During the congress, global experts including Academician Teng Gaojun, President Li Jiaping of Guangzhou Medical University Affiliated Cancer Hospital, Director Li Wentao of the Interventional Therapy Department at Fudan University Shanghai Cancer Center, Professor Long Jiao of The Royal Marsden Hospital in the UK, Professor Hicham Kobeiter of Henri Mondor University Hospital in France, Professor Shuichiro Shiina of the Sasaki Institute in Japan, and former APSCVIR President Professor Alex Tang gathered at the launch event to witness the global debut of the “i” series multimodal tumor treatment technology. This marks the official entry of solid tumor treatment into a new intelligent “interventional immunotherapy” era.
The new “i” series platform achieves a groundbreaking intelligent upgrade. Its core breakthrough lies in the introduction of digital twin technology, creating personalized digital tumor models for each patient to simulate, predict, and guide the spatial distribution of the energy field in real time. Preoperatively, precise treatment planning for the lesion is performed through image fusion; intraoperatively, personalized parameters such as tumor density, blood perfusion, and impedance are collected to achieve thermal dose regulation and real-time temperature field tracking display; postoperatively, comprehensive treatment effect prediction and assessment are possible. This means clinicians can move away from traditional empirical operations and achieve “tailor-made” personalized precision treatment.
To optimize clinical operations, the “i” series also innovatively features a split-type ultra-lightweight ablation probe, weighing as little as 18 grams. Its ergonomic design significantly improves surgical workflow and puncture freedom, substantially reducing the burden on the operator.
Conceptual Resonance: International Experts Deeply Interpret Clinical Value
During multiple keynote speeches at this congress, Meijie Medical’s multimodal tumor treatment technology was repeatedly cited as an innovative example. In his report titled “Interventional Radiology in China: New Horizons,” Academician Teng Gaojun specifically noted that original achievements represented by Meijie Medical’s multimodal technology are profoundly reshaping the landscape of precision tumor treatment with their innovative approach.
Professor Long Jiao of The Royal Marsden Hospital in the UK highly praised the technology, stating that it can achieve both precise local radical treatment and simultaneously activate the body’s own anti-tumor immune response through an in-situ vaccine effect, aligning perfectly with the concept of personalized precision therapy. Professor Li Wentao, from the perspective of interventional radiology, pointed out that this technology can stimulate anti-tumor immunity in situ, effectively reducing the risk of recurrence and metastasis. Particularly in preliminary clinical studies on primary liver cancer and pancreatic cancer, it has demonstrated breakthrough value in transforming “cold tumors” into “hot tumors,” opening a new path for interventional immunotherapy.
Global Attention: Ushering in a New Era of Interventional Immunotherapy
Throughout the congress, Meijie Medical’s booth maintained high visitor traffic, with experts and scholars from Asia-Pacific, Europe, and other countries showing strong interest and high praise for the “i” series’ precise, intelligent, and immune-activating integrated solution. Global experts unanimously agreed that the “i” series multimodal ablation technology balances precise local minimally invasive inactivation with systemic immune response, providing an ideal technological platform for interventional immunotherapy of solid tumors.
From proven efficacy published in international journals to the new intelligent platform brought by the “i” series, Meijie Medical is redefining the treatment paradigm for solid tumors with its cutting-edge multimodal thermophysical immune technology. It offers a “Chinese solution” integrating precision, intelligence, efficiency, and immune activation for the global field of minimally invasive tumor treatment, leading the way into a new era of interventional immunotherapy for solid tumors.